



All

Images

Videos

翻译成中文

关闭取词

28,000 Results

Any time ▼

HER2 testing in gastric cancer: An update

www.ncbi.nlm.nih.gov › ... › v.22(19); 2016 May 21

May 21, 2016 · The key differences between HER2 expression in breast and gastric and gastroesophageal cancer are listed[17,30]: (1) the membranous distribution of the antibody in the neoplastic cells of breast cancer is predominantly circumferential, whereas in gastric cancer, it is generally incomplete, predominantly basolateral ("U"-shaped) or lateral (parallel lines) (Figure ...

Cited by: 21

Author: Lucas Faria Abrahao-Machado, Cristova...

Publish Year: 2016

[PDF] Clinical impact of intratumoral HER2 heterogeneity on ...

<https://link.springer.com/content/pdf/10.1007/s00535-018-1464-0.pdf>

Its amplification or protein overexpression is shown in up to 20% of cases in gastric cancer [9–11], suggesting that it is a critical driver oncogene and, therefore, a promising treatment target.

Trastuzumab, full humanized anti-HER2 antibody, has been successfully developed in HER2-positive breast cancer [12, 13].

Cited by: 2

Author: Takeru Wakatsuki, Noriko Yamamoto, Ta...

Publish Year: 2018

Clinical significance of intratumoral HER2 heterogeneity ...

<https://www.sciencedirect.com/science/article/pii/S0959804912008404>

Intratumoral heterogeneity of HER2 overexpression was defined as the presence of $\geq 5\%$ and $\leq 50\%$ of the tumour cells with HER2 IHC 2+ or 3+, whereas cases showing IHC 2+ or 3+ in $\geq 50\%$ of the tumour cells were considered to have homogeneous HER2 overexpression in the whole section.

Cited by: 126

Author: Hee Eun Lee, Kyoung Un Park, Seol Bon...

Publish Year: 2013

The genomics and therapeutics of HER2-positive gastric ...

jgo.amegroups.com/article/view/8458/html ▼

Due to the **higher rate of tumor heterogeneity** and incomplete membranous **reactivity** seen in **gastric cancer** compared to **breast cancer** an IHC scoring criteria specific for **HER2-overexpression in gastric cancer** was devised . The IHC staining pattern that determines the highest level of **HER2 expression** by IHC (IHC 3+) is different depending on whether a surgical specimen or biopsy is tested.

Cited by: 9

Author: Ciara M. Kelly, Yelena Y. Janjigian

Publish Year: 2016

HER2 testing in gastric cancer: a practical approach ...

www.nature.com › modern pathology

1 **Name of Journal:** *World Journal of Clinical Cases*

2 **Manuscript NO:** 48191

3 **Manuscript Type:** ORIGINAL ARTICLE

4

5 *Retrospective Study*

6 **HER2 heterogeneity is a poor prognosticator for HER2 positive gastric cancer**

7

8 Kaito A *et al.* HER2 heterogeneity in gastric cancer

9

10 Akio Kaito, Takeshi Kuwata, Masanori Tokunaga, Kohei Shitara, Reo Sato,

11 Tetsuo Akimoto, Takahiro Kinoshita

12

Match Overview

1	Crossref 48 words Fuse, Nozomu, Yasutoshi Kuboki, Takeshi Kuwata, Tomohiro Nishina, Shigenori Kadowaki, Eiji Shinozaki, Nozo	1%
2	Crossref 33 words Hye Kyung Jeon, Gwang Ha Kim, Bong Eun Lee, Do Youn Park, Geun Am Song, Dae Hwan Kim, Tae Yong Jeon.	1%
3	Internet 31 words crawled on 27-Mar-2015 paperity.org	1%
4	Internet 29 words crawled on 16-May-2019 www.tandfonline.com	1%
5	Crossref 18 words Yasuhiro Oono, Takeshi Kuwata, Kenji Takashima, Kensuke Shinmura et al. "Human epidermal growth factor rec	1%
6	Internet 17 words crawled on 12-Jun-2019 www.nature.com	<1%
7	Internet 15 words crawled on 25-Apr-2019 breast-cancer-research.biomedcentral.com	<1%
8	Internet 15 words crawled on 26-Dec-2018 www.science.gov	<1%
9	Crossref 14 words Muzaffar H. Qazilbash, Rima M. Saliba, Ana Aleman, X. Lei, Donna Weber, Antonio Carrasco, Richard E. Champli	<1%
10	Internet 13 words crawled on 31-Jan-2019 www.wjgnet.com	<1%
11	Crossref 13 words Yan-Xia Shi, Yu-Ting Tan, Zhong-Yu Yuan, Shu-Sen Wang et al. "Comparison of overall survival between the early	<1%



国内版

国际版

HER2 heterogeneity is a poor prognosticator for HER2 positive gastric cancer



All

Images

Videos

翻译成中文

关闭取词

29,500 Results

Any time ▾

HER2 testing in gastric cancer: An update

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870069>

May 21, 2016 - Thus, unlike for breast cancer, circularity of IHC staining is not a criterion for HER2 IHC scoring in gastric cancer; (2) intratumoral heterogeneity, defined as the presence of areas with different HER2 scores within the same tumor, i.e., focal or patchy positivity, is a common pattern encountered in gastric tumors but is only rarely seen in ...

Cited by: 25

Author: Lucas Faria Abrahao-Machado, Cristova...

Publish Year: 2016

HER2 heterogeneity in gastric/gastroesophageal cancers ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948273>

Jul 14, 2016 - HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. In these types of cancer, accurate assessment of HER2 status is mandatory, for selecting patients who may benefit from targeted therapies with anti-HER2 drugs such as Trastuzumab.

Cited by: 16

Author: Federica Grillo, Matteo Fassan, Francesc...

Publish Year: 2016

Pertuzumab therapy for HER2-positive metastatic gastric or ...

[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(18\)30512-6/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30512-6/fulltext)

Sep 11, 2018 - In The Lancet Oncology, Josep Tabernero and colleagues¹ report the final analysis of the JACOB trial, which tested the efficacy and safety of pertuzumab (a monoclonal antibody targeting HER2 receptors) combined with trastuzumab and chemotherapy in previously untreated patients with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.

Cited by: 1

Author: Giandomenico Roviello, Daniele Generali

Publish Year: 2018

HER2 Heterogeneity Affects Trastuzumab Responses and ...

<https://academic.oup.com/ajcp/article/142/6/755/1766313> ▾

Jan 12, 2014 - HER2 heterogeneity has been found in a subset of breast cancers, in which it has been linked to low-level HER2 amplification or equivocal HER2 expression. Its importance is increasingly being recognized not only in breast cancer but also in other cancers, including gastric and esophageal adenocarcinoma.

Cited by: 59

Author: Hee Jin Lee, Hee Jin Lee, An Na Seo, Eu...

Publish Year: 2014

Author: Lee, Hee Jin



国内版

国际版

HER2 heterogeneity is a poor prognosticator for HER2 positive gastric cancer



All

Images

Videos

翻译成中文

开启取词

29,900 Results

Any time ▾

HER2 heterogeneity in gastric/gastroesophageal cancers ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948273>

Jul 14, 2016 · **HER2** is overexpressed in approximately 10%-20% of **gastric** and gastroesophageal junction carcinomas. In these types of **cancer**, accurate assessment of **HER2** status is mandatory, for selecting patients who may benefit from targeted therapies with anti-**HER2** drugs such as Trastuzumab.

Cited by: 16

Author: Federica Grillo, Matteo Fassan, Francesc...

Publish Year: 2016

HER2 testing in gastric cancer: An update

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870069>

May 21, 2016 · Thus, unlike for breast **cancer**, circularity of IHC staining is not a criterion for **HER2** IHC scoring in **gastric cancer**; (2) intratumoral **heterogeneity**, defined as the presence of areas with different **HER2** scores within the same tumor, i.e., focal or patchy positivity, is a common pattern encountered in **gastric** tumors but is only rarely seen in ...

Cited by: 25

Author: Lucas Faria Abrahao-Machado, Cristova...

Publish Year: 2016

The genomics and therapeutics of HER2-positive gastric ...

jgo.amegroups.com/article/view/8458/html ▾

The future directions of clinical investigation in **HER2-positive gastric cancer** are also discussed including: novel **HER2**-directed therapies, the pharmacokinetics and pharmacodynamics of anti-**HER2**-therapies, the role of functional imaging, the potential of patient derived xenograft preclinical models and the importance of tumor genomic sequencing.

Cited by: 10

Author: Ciara M. Kelly, Yelena Y. Janjigian

Publish Year: 2016

Clinical significance of intratumoral HER2 heterogeneity ...

<https://www.sciencedirect.com/science/article/pii/S0959804912008404>

Intratumoral heterogeneity of **HER2 overexpression** was defined as the presence of $\geq 5\%$ and $\leq 50\%$ of the **tumour cells** with **HER2 IHC 2+** or **3+**, whereas cases showing **IHC 2+** or **3+** in $\geq 50\%$ of the **tumour cells** were considered to have **homogeneous HER2 overexpression** in the whole section.

Cited by: 115

Author: Hee Eun Lee, Kyoung Un Park, Seol Bon...

Publish Year: 2013

Related searches

her2 in gastric cancer

her2 **expression** in gastric cancerher2 **negative** cancer **treatment**her2 **testing** in gastric cancerher2 positive cancer **survival rate**her2 positive cancer **diet**her2 gastric cancer **statistics**her2 **stomach** cancer **outcomes**